AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2959626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 362293 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy (1 mg Corynebacterium parvum i.v. on days 1-4 + MeCCNU 200 mg/m2 on day 8, repeated every 7 weeks)
Number of subjects: 34
Study 362293 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (MeCCNU, 200 mg/m2, given orally every 8 weeks)
Number of subjects: 34
Study 362293 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy (C. parvum + MeCCNU)
Number of subjects: 34
Study 362293 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (MeCCNU)
Number of subjects: 34
Study 31742881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 1259
Study 31742881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1259
Study 31134272 — intervention group
Group type: EXPERIMENTAL
Intervention: Flock weight uniformity (CV of BW)
Number of subjects: 45
Study 28345792 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with faster aspart (n=116)
Number of subjects: 236
Study 28345792 — intervention group
Group type: COMPARATOR
Intervention: Basal-only insulin (n=120)
Number of subjects: 236
Study 25771851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 32
Study 25771851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23741880 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-MOSCOW (3-33 x 10(5) cells), injected intra-dermally at 3 month intervals (Gr A)
Number of subjects: 107
Study 23741880 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.85%), injected intra-dermally at 3 month intervals (Gr B)
Number of subjects: 107
Study 23741880 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-MOSCOW (Gr A)
Number of subjects: 107
Study 23741880 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Gr B)
Number of subjects: 107
Study 22152769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufei Yishen Granule combined with acupoint‐sticking therapy
Number of subjects: 244
Study 22152769 — intervention group
Group type: COMPARATOR
Intervention: Sustained‐release theophylline (control)
Number of subjects: 244
Study 19095990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 588
Study 19095990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific ST- and T-wave abnormalities
Number of subjects: 588
Study 17185398 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-reducing decorated butterfly needles and syringes
Number of subjects: 50
Study 17185398 — intervention group
Group type: COMPARATOR
Intervention: Conventional needles and syringes
Number of subjects: 50
Study 15061044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser irradiation (LLLI), 10 sessions
Number of subjects: 47
Study 15061044 — intervention group
Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 47
Study 15061044 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermographic response to cold challenge
Number of subjects: 47
Study 11506061 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 44
Study 11506061 — intervention group
Group type: EXPERIMENTAL
Intervention: High iron diet
Number of subjects: 44
Study 11506061 — intervention group
Group type: COMPARATOR
Intervention: Iron replete women (control group)
Number of subjects: 44
Study 9625090 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mL preload
Number of subjects: 20
Study 9625090 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mL preload
Number of subjects: 20
Study 9625090 — intervention group
Group type: EXPERIMENTAL
Intervention: 450-mL preload
Number of subjects: 20
Study 9625090 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no drink)
Number of subjects: 20
Study 9625090 — intervention group
Group type: EXPERIMENTAL
Intervention: All preloads
Number of subjects: 20
Study 7941664 — intervention group
Group type: EXPERIMENTAL
Intervention: High work rate cycle ergometer training for 45 min/day
Number of subjects: 19
Study 7941664 — intervention group
Group type: COMPARATOR
Intervention: Low work rate cycle ergometer training for a proportionally longer time
Number of subjects: 19
Study 3356742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning with 70% isopropyl alcohol prior to catheter removal (Group 1)
Number of subjects: 50
Study 3356742 — intervention group
Group type: COMPARATOR
Intervention: No cleaning prior to catheter removal (Group 2)
Number of subjects: 50
Study 3356742 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 50
Study 3356742 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures
Number of subjects: 50
Study 30442165 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention
Number of subjects: 746
Study 28086851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 60
Study 28086851 — intervention group
Group type: COMPARATOR
Intervention: 10-Hz high-frequency repetitive transcranial magnetic stimulation (HF-rTMS)
Number of subjects: 60
Study 26316562 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 13
Study 26316562 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 13
Study 23724875 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 10
Study 21036173 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG alfa-2a (PEG-2a; 180 μg/1.73 m(2) body surface area, subcutaneously each week) and ribavirin (15 mg/kg orally in 2 doses daily)
Number of subjects: 114
Study 21036173 — intervention group
Group type: COMPARATOR
Intervention: PEG alfa-2a (PEG-2a) and placebo
Number of subjects: 114
Study 21036173 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG alfa-2a (PEG-2a) and ribavirin
Number of subjects: 114
Study 18460701 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil 16 mg
Number of subjects: 206
Study 18460701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 16895883 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) breakfast
Number of subjects: 8
Study 16895883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) breakfast
Number of subjects: 8
Study 15252294 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (0, 2, and 4 g, p.o.)
Number of subjects: 0
Study 11333096 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL fibrin sealant at axillary dissection site
Number of subjects: 0
Study 11333096 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mL fibrin sealant at axillary dissection site and 8 mL at skin flap site
Number of subjects: 0
Study 11333096 — intervention group
Group type: COMPARATOR
Intervention: Control (no agent)
Number of subjects: 0
Study 9052310 — intervention group
Group type: EXPERIMENTAL
Intervention: Augustine Scope (AS)
Number of subjects: 200
Study 9052310 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 200
Study 8136395 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine and ketorolac
Number of subjects: 0
Study 8136395 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine and morphine
Number of subjects: 0
Study 3027153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, 4 mg from a metered-dose inhaler
Number of subjects: 12
Study 3027153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium, 20 mg from a Spinhaler
Number of subjects: 12
Study 3027153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31978225 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by maintenance lenalidomide
Number of subjects: 301
Study 31978225 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by placebo
Number of subjects: 301
Study 28954826 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+F (standard CR with additional face-to-face active lifestyle counselling and group fitness training)
Number of subjects: 914
Study 28954826 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+T (standard CR extended with telephone lifestyle counselling)
Number of subjects: 914
Study 28954826 — intervention group
Group type: COMPARATOR
Intervention: CR-only (standard CR)
Number of subjects: 914
Study 26986056 — intervention group
Group type: EXPERIMENTAL
Intervention: History of child trauma and poor mental health (PTSD, depressive symptoms, alcohol abuse)
Number of subjects: 416
Study 26986056 — intervention group
Group type: EXPERIMENTAL
Intervention: History of child trauma
Number of subjects: 416
Study 26986056 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptomatology
Number of subjects: 416
Study 26986056 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly equitable gender attitudes
Number of subjects: 416
Study 26986056 — intervention group
Group type: EXPERIMENTAL
Intervention: Child trauma, other trauma, PTSD
Number of subjects: 416
Study 26986056 — intervention group
Group type: EXPERIMENTAL
Intervention: Child trauma
Number of subjects: 416
Study 24765899 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) 0 mg (control)
Number of subjects: 60
Study 24765899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.3 mg
Number of subjects: 60
Study 24765899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.1 mg
Number of subjects: 60
Study 24765899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.2 mg
Number of subjects: 60
Study 23539257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg once daily
Number of subjects: 16
Study 23539257 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (ethinylestradiol 0.035 mg + norethisterone 1 mg)
Number of subjects: 16
Study 20630168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplementation (MVM)
Number of subjects: 200
Study 20630168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18528407 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed device for measuring carotid-femoral PWV
Number of subjects: 21
Study 18528407 — intervention group
Group type: COMPARATOR
Intervention: Standard device (Complior) for measuring carotid-femoral PWV
Number of subjects: 21
Study 18528407 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-ankle PWV
Number of subjects: 21
Study 16931264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL injection volume of peribulbar anesthesia
Number of subjects: 20
Study 16931264 — intervention group
Group type: COMPARATOR
Intervention: 2 mL injection volume of peribulbar anesthesia
Number of subjects: 20
Study 12601528 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Number of subjects: 0
Study 12601528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10973836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide infusion for up to 72 to 96 hours
Number of subjects: 4035
Study 10973836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4035
Study 8793039 — intervention group
Group type: EXPERIMENTAL
Intervention: Competence training
Number of subjects: 309
Study 8793039 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 309
Study 8793039 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor training
Number of subjects: 309
Study 8793039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psychomotor and memory training
Number of subjects: 309
Study 8793039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 309
Study 1467860 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation (mean of 15 litres of irrigating fluid used)
Number of subjects: 200
Study 1467860 — intervention group
Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 200
Study 1467860 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation
Number of subjects: 200
Study 6421249 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐SP (spansule)
Number of subjects: 126
Study 6421249 — intervention group
Group type: COMPARATOR
Intervention: Gastro‐soluble tegafur (control)
Number of subjects: 126
Study 6421249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 126
Study 30872737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo (TXL)
Number of subjects: 1212
Study 30872737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study 29600482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% with 1:400 000 epinephrine)
Number of subjects: 6
Study 29600482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.4 mL·kg‐1 of 0.9% saline)
Number of subjects: 6
Study 29600482 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 6
Study 26658804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution and polyethylene glycol electrolyte powder
Number of subjects: 90
Study 26658804 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol electrolyte powder only
Number of subjects: 90
Study 24577471 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 17
Study 24577471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22471290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg twice daily
Number of subjects: 173
Study 22471290 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 173
Study 22471290 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 200 mg once daily
Number of subjects: 173
Study 20499122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and standard physical therapy (group III)
Number of subjects: 45
Study 20499122 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound in addition to standard physical therapy (group II)
Number of subjects: 45
Study 20499122 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy including hot pack and exercise program (group I)
Number of subjects: 45
Study 17110604 — intervention group
Group type: EXPERIMENTAL
Intervention: GW501516 10 mg
Number of subjects: 24
Study 17110604 — intervention group
Group type: EXPERIMENTAL
Intervention: GW501516 2.5 mg
Number of subjects: 24
Study 17110604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16120074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg
Number of subjects: 11
Study 16120074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11975715 — intervention group
Group type: EXPERIMENTAL
Intervention: 13Leu‐motilin
Number of subjects: 8
Study 11975715 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (saline)
Number of subjects: 8
Study 11975715 — intervention group
Group type: EXPERIMENTAL
Intervention: motilin + ondansetron
Number of subjects: 8
Study 11975715 — intervention group
Group type: EXPERIMENTAL
Intervention: motilin
Number of subjects: 8
Study 10419240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornstarch (0.3 g/kg)
Number of subjects: 14
Study 10419240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7593726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg daily)
Number of subjects: 147
Study 7593726 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (150 mg daily)
Number of subjects: 147
Study 2292549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/azlocillin
Number of subjects: 108
Study 2292549 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/azlocillin
Number of subjects: 108
Study 7205167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin administered twice a day
Number of subjects: 154
Study 7205167 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin administered four times a day
Number of subjects: 154
Study 30734465 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating RNAs (miRNAs)
Number of subjects: 57
Study 30094983 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal cake-partitioned moxibustion combined with Rhinocort nasal spray (2 jets/day for each nostril, 64 µg/jet) for 8 weeks
Number of subjects: 60
Study 30094983 — intervention group
Group type: COMPARATOR
Intervention: Rhinocort nasal spray (2 jets/day for each nostril, 64 µg/jet) for 8 weeks
Number of subjects: 60
Study 27322311 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven(®) 10% 100 mL/day for five days postoperatively
Number of subjects: 119
Study 27322311 — intervention group
Group type: COMPARATOR
Intervention: Regular nutrition
Number of subjects: 119
Study 24072724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation for 12 weeks
Number of subjects: 18
Study 24072724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 21542114 — intervention group
Group type: EXPERIMENTAL
Intervention: IV normal saline (NS) ± N-acetylcysteine (NAC) (n = 161)
Number of subjects: 320
Study 21542114 — intervention group
Group type: COMPARATOR
Intervention: IV sodium bicarbonate (NaHCO(3)) ± NAC (n = 159)
Number of subjects: 320
Study 19358990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.25 mg/kg
Number of subjects: 90
Study 19358990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 90
Study 19358990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17767511 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg
Number of subjects: 14
Study 17767511 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 1000 mg
Number of subjects: 14
Study 17767511 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 14
Study 16582548 — intervention group
Group type: EXPERIMENTAL
Intervention: MORA bioresonance therapy
Number of subjects: 20
Study 16582548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12013159 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and counselling intervention performed by a senior doctor
Number of subjects: 53
Study 12013159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 9678615 — intervention group
Group type: COMPARATOR
Intervention: Group A - letter signed by the GP, with a prefixed appointment
Number of subjects: 16454
Study 9678615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - open-ended invitation, signed by the GP
Number of subjects: 16454
Study 9678615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - letter signed by the program coordinator, with a prefixed appointment
Number of subjects: 16454
Study 9678615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D - extended letter signed by the GP, with a prefixed appointment
Number of subjects: 16454
Study 8583221 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial cases of Parkinson's disease
Number of subjects: 31
Study 8583221 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at onset in familial cases
Number of subjects: 31
Study 8583221 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at onset within a generation
Number of subjects: 31
Study 8583221 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic transmission
Number of subjects: 31
Study 8583221 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete penetrance
Number of subjects: 31
Study 2696648 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 111
Study 2696648 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 111
Study 57244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiacetazone 150 mg with Isoniazid 300 mg once daily
Number of subjects: 72
Study 57244 — intervention group
Group type: COMPARATOR
Intervention: Paraaminosalicyclic acid 12 gm with Isoniazid 300 mg daily in divided doses
Number of subjects: 72
Study 30782715 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity training programme (3 sessions of 45 minutes per week for 2 years)
Number of subjects: 110
Study 30782715 — intervention group
Group type: COMPARATOR
Intervention: Low intensity training programme (3 sessions of 45 minutes per week for 2 years)
Number of subjects: 110
Study 27789238 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from significant others, family members, and friends
Number of subjects: 163
Study 27789238 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience (measured using the Connor‐Davidson Resilience Scale)
Number of subjects: 163
Study 26306000 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS plus optimal drug therapy (DBS + ODT)
Number of subjects: 0
Study 26306000 — intervention group
Group type: COMPARATOR
Intervention: Optimal drug therapy (ODT)
Number of subjects: 0
Study 23207188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged chewing (30 seconds per mouthful)
Number of subjects: 43
Study 23207188 — intervention group
Group type: COMPARATOR
Intervention: Habitual chewing
Number of subjects: 43
Study 23207188 — intervention group
Group type: COMPARATOR
Intervention: Habitual chewing with pauses
Number of subjects: 43
Study 23207188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged chewing
Number of subjects: 43
Study 23207188 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study 20828790 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg bid
Number of subjects: 1020
Study 20828790 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg bid
Number of subjects: 1020
Study 20828790 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg bid
Number of subjects: 1020
Study 20828790 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1020
Study 18708688 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR: 0.25 g/kg lean-tissue mass for 7 days; 0.06 g/kg lean-tissue mass for 49 days; n=22, 12 males, 10 females)
Number of subjects: 42